Your browser doesn't support javascript.
loading
Modification of peanut allergen Ara h 3: effects on IgE binding and T cell stimulation.
Rabjohn, Pat; West, C Michael; Connaughton, Cathie; Sampson, Hugh A; Helm, Ricki M; Burks, A Wesley; Bannon, Gary A.
Afiliación
  • Rabjohn P; Department of Biochemistry and Molecular Biology, Arkansas Children's Hospital Research Institute, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA.
Int Arch Allergy Immunol ; 128(1): 15-23, 2002 May.
Article en En | MEDLINE | ID: mdl-12037397
BACKGROUND: Peanut allergy is a major health concern due to the increased prevalence, potential severity, and chronicity of the reaction. The cDNA encoding a third peanut allergen, Ara h 3, has been previously cloned and characterized. Mutational analysis of the Ara h 3 IgE-binding epitopes with synthetic peptides revealed that single amino acid changes at critical residues could diminish IgE binding. METHODS: Specific oligonucleotides were used in polymerase chain reactions to modify the cDNA encoding Ara h 3 at critical IgE binding sites. Four point mutations were introduced into the Ara h 3 cDNA at codons encoding critical amino acids in epitopes 1, 2, 3 and 4. Recombinant modified proteins were used in SDS-PAGE/Western IgE immunoblot, SDS-PAGE/Western IgE immunoblot inhibition and T cell proliferation assays to determine the effects of these changes on in vitro clinical indicators of peanut hypersensitivity. RESULTS: Higher amounts of modified Ara h 3 were required to compete with the wild-type allergen for peanut-specific serum IgE. Immunoblot analysis with individual serum IgE from Ara-h-3-allergic patients showed that IgE binding to the modified protein decreased approximately 35-85% in comparison to IgE binding to wild-type Ara h 3. Also, the modified Ara h 3 retained the ability to stimulate T cell activation in PBMCs donated by Ara-h-3-allergic patients. CONCLUSIONS: The engineered hypoallergenic Ara h 3 variant displays two characteristics essential for recombinant allergen immunotherapy; it has a reduced binding capacity for serum IgE from peanut-hypersensitive patients and it can stimulate T-cell proliferation and activation.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Alérgenos Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Int Arch Allergy Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2002 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Alérgenos Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Int Arch Allergy Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2002 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza